Marta Chesi, PhD

Assistant Professor

  • 8460 Citations
  • 36 h-Index
19962020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Receptor, Fibroblast Growth Factor, Type 3 Medicine & Life Sciences
Tumors Chemical Compounds
Monoclonal Gammopathy of Undetermined Significance Medicine & Life Sciences
Plasma Cells Medicine & Life Sciences
Polyploidy Medicine & Life Sciences
Cells Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2020

Multiple Myeloma
Oncolytic Virotherapy
Clonal Evolution
Vesicular Stomatitis
Research
Multiple Myeloma
Immunotherapy
Standard of Care
Phase II Clinical Trials
Pharmaceutical Preparations

Research Output 1996 2019

1 Citation (Scopus)

Bone marrow transplantation generates T cell-dependent control of myeloma in mice

Vuckovic, S., Minnie, S. A., Smith, D., Gartlan, K. H., Watkins, T. S., Markey, K. A., Mukhopadhyay, P., Guillerey, C., Kuns, R. D., Locke, K. R., Pritchard, A. L., Johansson, P. A., Varelias, A., Zhang, P., Huntington, N. D., Waddell, N., Chesi, M., Miles, J. J., Smyth, M. J. & Hill, G. R., Jan 2 2019, In : Journal of Clinical Investigation. 129, 1, CI98888.

Research output: Contribution to journalArticle

Bone Marrow Transplantation
T-Lymphocytes
Autologous Transplantation
Tissue Donors
Multiple Myeloma

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Thirukkumaran, C. M., Shi, Z. Q., Nuovo, G. J., Luider, J., Kopciuk, K. A., Dong, Y., Mostafa, A. A., Thakur, S., Gratton, K., Yang, A., Chin, A. C., Coffey, M. C., Jimenez-Zepeda, V. H., Stewart, D., Chesi, M., Bergsagel, P. L. & Morris, D., Mar 12 2019, In : Blood advances. 3, 5, p. 797-812 16 p.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Immunotherapy
Survival
Neoplasms
Therapeutics

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., Parker, T., Munshi, N. C., Sexton, R., Barlogie, B., Orlowski, R., Bergsagel, P. L., Hose, D., Flavell, R. A., Mistry, P. K., Meffre, E. & 1 othersDhodapkar, M. V., Apr 19 2018, In : JCI insight. 3, 8

Research output: Contribution to journalArticle

Open Access
Paraproteinemias
Antigens
Gaucher Disease
Plasma Cells
Multiple Myeloma
4 Citations (Scopus)

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression

Kawano, Y., Zavidij, O., Park, J., Moschetta, M., Kokubun, K., Mouhieddine, T. H., Manier, S., Mishima, Y., Murakami, N., Bustoros, M., Pistofidis, R. S., Reidy, M., Shen, Y. J., Rahmat, M., Lukyanchykov, P., Karreci, E. S., Tsukamoto, S., Shi, J., Takagi, S., Huynh, D. & 7 othersSacco, A., Tai, Y. T., Chesi, M., Bergsagel, P. L., Roccaro, A. M., Azzi, J. & Ghobrial, I. M., Jun 1 2018, In : Journal of Clinical Investigation. 128, 6, p. 2487-2499 13 p.

Research output: Contribution to journalArticle

Interferon Type I
Immunosuppressive Agents
Multiple Myeloma
Immunosuppression
Regulatory T-Lymphocytes
4 Citations (Scopus)

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

Nakamura, K., Kassem, S., Cleynen, A., Chrétien, M. L., Guillerey, C., Putz, E. M., Bald, T., Förster, I., Vuckovic, S., Hill, G. R., Masters, S. L., Chesi, M., Bergsagel, P. L., Avet-Loiseau, H., Martinet, L. & Smyth, M. J., Jan 1 2018, (Accepted/In press) In : Cancer Cell.

Research output: Contribution to journalArticle

Interleukin-18
Multiple Myeloma
Immunosuppression
Therapeutics
T-Lymphocytes